Ann: Half Year Report and Financial Statements, page-13

''Whilst, and this definitely is not my opinion btw, we lack the charisma and leaders to excite people and get investors on board,''

BT..This isn't a question of opinion...it's fact..the share price and share register are proof of this. It's incontrovertible

It's interesting that you use the example on Innate Immuno. Yes, you are right that the trial failed and the stock collapsed. What you fail to mention is that for every person who held to the time of the trial result, another 100 others traded in and out of the stock all the way up to $1.80 and many would have made huge profits along the way

The point is that their leadership did have the charisma and were able to generate sufficient interest in the science ts push the stock up to a market cap of a few hundred million. Let's not forget that probably 1% of holders held from the outset to the trial result, because about 99% of the trials fail

So it's easy to choose a point in time to support your conclusion. Fact is DXB have been an appalling failure at generating interest in the company and this has meant that none of us have had the choice to exit with a decent profit on the way to final trial results....this is an opportunity that investors in pretty much every other biotech I have seen have had the chance to do

We are now prisoners to the trial results, and , as we know in biotech, nothing is without substantial risk

So I remain hugely frustrated and disappointed with DXB's Board and management and i still believe they lag other biotech stocks massively in this regard